This site is intended for healthcare professionals
CSU Learning Zone
Declaration of sponsorship Novartis Pharma AG and J. Uriach y Compañía S.A

CSU Resources

Declaration of sponsorship Novartis Pharma AG and J. Uriach y Compañía S.A
Read time: 230 mins
Last updated:27th Jun 2022
Published:29th Oct 2021

Improve your ability to diagnose and manage patients with chronic spontaneous urticaria (CSU).

  • Discover “All Things Urticaria”, a podcast series brought to you by the UCARE network
  • Receive 1 European CME credit when you complete our interactive EACCME-accredited module
  • Revisit independently led highlights of the EAACI 2021 and EADV 2020 annual conferences

Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG

All Things Urticaria: Podcasts

The following podcasts are brought to you by the Urticaria Centres of Reference and Excellence (UCARE) network. The UCARE network aims to provide excellence in urticaria management, increase knowledge of urticaria via research, studies, and education, and promote awareness of urticaria through advocacy activities1. In these podcasts our host, Professor Marcus Maurer, is joined by his friends and colleagues to discuss ‘All Things Urticaria’.

Episode 43: Chronic Urticaria: A South African Perspective

Hear Associate Professor Jonathan Peter (Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town, South Africa; Allergy and Immunology Unit, University of Cape Town Lung Institute, South Africa) explain regional differences in urticaria in South Africa, with a focus on epidemiology, patient beliefs and education, and the CRUSE App.

Episode 42: Chronic Urticaria: A Latin American Perspective

In this episode, Dr Maximiliano Gómez shares his tips and tricks for improving the diagnosis and management of chronic urticaria and calls for wider dissemination of good quality information to patients living in Argentina and beyond. 

Episode 41: Chronic Urticaria: A Middle Eastern Perspective

Dr Mona Al-Ahmad joins the podcast from the UCARE centre in Kuwait to share her insights into the UCARE network’s Middle Eastern activities. Dr Al-Ahmad also takes time to reflect on what more can be done to improve the lives of people living with chronic urticaria and those caring for them.

Episode 40: Chronic Urticaria: An Indian Perspective 

In this episode, our host is joined by Professor Kiran Godse who shares his experiences of treating CSU in India. Professor Godse provides unmissable insights into the practicalities of CSU care, including economic considerations, as well as his plans to increase the UCARE network’s presence in India and facilitate wider dissemination of educational resources. 

Episode 39: Chronic Urticaria: A North American Perspective 

Professor Jonathan Bernstein joins the podcast to discuss chronic urticaria (CU) care in the USA. In this episode, Professor Bernstein shines a light on the challenges faced by US-based physicians and highlights the potential benefits of conducting further research into the diverse population living with CU in North America.

Episode 38: UCARE Behind the Scenes Special (Part 2)

In part two of this very special episode, Professor Marcus Maurer is joined once again by his colleagues from the UCARE office to discuss the UCARE LevelUp and UCARE 4U programmes, which aim to inform and educate patients and physicians on the management of chronic urticaria. To find out more information on UCARE, please visit ga2len-ucare.com.

Episode 37: UCARE Behind the Scenes Special (Part 1)

In this very special two-part episode, Professor Marcus Maurer is joined by not one, but four of his UCARE office colleagues to give listeners exclusive insight into the inner workings of the UCARE network, including advice on how to become a UCARE centre and updates on exciting new UCARE initiatives. 

Episode 36: Are you CSU aware?

In this episode, our host is joined by Dr Christian Vestergaard, who offers expert insight into the results of the AWARE study and highlights the urgent need for wider dissemination of the guidelines for CSU management.

Episode 35: CRUSE CONTROL: A Chronic Urticaria Self-Evaluation App

In this episode, Dr Sophia Neisinger joins the podcast to introduce the CRUSE CONTROL app, which has been developed to help support chronic spontaneous urticaria self-evaluation and aims to improve patient quality of life. 

Episode 34: Improving urticaria education: an international perspective

In this episode, Dr Désirée Larenas-Linnemann joins our host to discuss the importance of providing better education on urticaria for patients and physicians around the world. Dr Larenas-Linnemann also highlights international differences in educational needs and the role of UCARE programmes in addressing these.

Episode 33: Paediatric Urticaria: Current Practice and Future Prospects

Dr Vicky Xepapadaki joins the podcast to share her knowledge of paediatric urticaria, including current treatment strategies and unmet needs. Dr Xepapadaki also reflects on the importance of involving parents in clinical decision-making and highlights some of the key differences between adult and paediatrics patients.

Episode 32: UCARE LevelUp

In this episode, Dr Iman Nasr discusses UCARE LevelUp, an educational program devised by the UCARE network to allow healthcare professionals to learn, network and share best clinical practices in chronic urticaria. Dr Nasr also touches on UCARE 4U, the UCARE patient information and education platform and programme.

Episode 31: The Role of PAF and Urticaria in Adults

In this episode, Dr Ana Gimenez discusses new insights into the pathology of chronic urticaria and how these insights can help guide treatment decisions. Dr Gimenez discusses the inflammatory mediators relevant in chronic urticaria, with a particular focus on platelet-activating factor (PAF). She describes the role of PAF, its contribution to the development of signs and symptoms of chronic urticaria, and why she considers PAF an important consideration in chronic spontaneous urticaria.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Explore exclusive video insights into the care and management of urticaria with this Meet the Experts webinar from October 2021. Join Professor Marcus Maurer and Professor Petra Staubach-Renz as they discuss highlights from the ‘All Things Urticaria’ podcast series, including:

  • Comorbidities in chronic urticaria
  • Reasons for delays in patient journeys through diagnosis and treatment
  • Predicting the duration of urticaria

Join the experts to discover the current and future treatment landscape for urticaria.

CSU with concomitant chronic inducible urticaria

5

Catch up on our ‘Meet the experts’ webinar created in collaboration with the UCARE network, which took place on 28th October 2021. In this 30-minute session our urticaria experts, Professors Marcus Maurer and Petra Staubach-Renz, reviewed the highlights of the ‘All Things Urticaria’ podcast series, including insights into the burden and treatment of comorbidities in patients with CSU, as well as unmet needs and the future of CSU management.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

EACCME-accredited module

Improving patient outcomes in chronic spontaneous urticaria

Despite the availability of improved treatment options for chronic spontaneous urticaria (CSU), this burdensome disease remains poorly controlled in a substantial proportion of patients. Launch our EACCME-accredited eLearning module to find out more about CSU and how it can be managed effectively.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

EADV Congress 2021

This year marks the 30th Annual Congress of the European Academy of Dermatology and Venereology (EADV). In the following videos, Professor Marcus Maurer is joined by Professor Martin Metz to review research presented at this year’s meeting, including their take on novel treatment approaches in chronic spontaneous urticaria (CSU) and insights into the future of urticaria management.

Bruton’s tyrosine kinase inhibition in chronic urticaria

2
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

EAACI Virtual 2021

Find out what you missed at the annual European Academy of Allergy and Clinical Immunology (EAACI) Congress as we revisit some of the best moments from this year’s meeting. In the following videos, Professor Marcus Maurer is joined by Dr Ana Giménez-Arnau to share their personal highlights and outline their hopes for the year to come.

Welcome and Introduction

Professor Marcus Maurer introduces himself and his friend and colleague Dr Ana Giménez-Arnau, before outlining the objectives of this session.

Favourite aspects from EAACI 2021

In the following video clip, Professor Maurer and Dr Giménez-Arnau share their favourite aspects of this year’s EAACI congress.

Impactful sessions for the field of urticaria

Professor Maurer and Dr Giménez-Arnau look back at the sessions they attended at EAACI 2021, and they share which sessions they believe will have the most impact in the field of urticaria and beyond.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

ACAAI Virtual 2020

Explore this section for updates in chronic spontaneous urticaria treatment and management from the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, held in 2020.

Day 1 of ACAAI: Exploring investigational therapies in CSU

Explore the results of two studies assessing the efficacy and achievement of symptom control of ligelizumab compared to omalizumab in patients with chronic spontaneous urticaria in the sessions below from ACAAI 2020

Ligelizumab is a next generation high-affinity monoclonal anti-IgE antibody that was developed to potentially overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE antibody omalizumab6.

Kicking off the first day of the American College of Allergy, Asthma & Immunology (ACAAI) 2020 Annual Scientific Meeting, we followed oral abstracts that summarise the results of two intriguing studies into ligelizumab for the treatment of chronic spontaneous urticaria (CSU). Ligelizumab is one of a number of novel treatments currently under development for the management of CSU. Other promising treatment options such as UB-221, interleukin 5-targeted monoclonal antibodies, chemoattractant receptor-homologous molecule expressed on TH2 cell antagonists, monoclonal antibodies to Siglec-8, Bruton tyrosine kinase inhibitors and spleen tyrosine kinase inhibitors, are also under investigation7.

Aiming for complete symptomatic control in patients with CSU

Characterised by itchy wheals and/or angioedema for six weeks or more in the absence of specific external stimuli, chronic spontaneous urticaria has a substantial impact on quality of life8. Treatment options with a faster action and sustained response have therefore been a key focus of research.

In a Phase 2b clinical trial, ligelizumab has previously demonstrated improved symptom control in patients with moderate to severe CSU inadequately controlled with H1-antihistamines9.

As part of the distinguished industry oral abstracts, Dr Thomas Severin shared the results of a study that analysed the early response after the first dose and sustainability over the first twelve weeks of ligelizumab (72 mg and 240 mg) compared to omalizumab (300 mg) in patients with CSU inadequately controlled with H1-antihistamines.

The results of this study showed that patients treated with 72 mg and 240 mg of ligelizumab achieved complete control of the disease, with an Urticaria Activity Score (UAS7) = 0, at a higher rate (20.5% and 18.1%, respectively) than omalizumab (10.7%) following the first dose. This trend continued throughout the following weeks of treatment until Week 12.

For patients who were well-controlled at Week 12, ligelizumab provided a greater and more stable response in terms of complete control of urticaria symptoms, compared with omalizumab, throughout the first twelve weeks of treatment.

The time to first response for patients who achieved complete and well-controlled urticaria was also faster in patients treated with ligelizumab than with omalizumab.

The efficacy of ligelizumab in patients inadequately controlled with omalizumab

Following the positive results of the Phase 2b core study of ligelizumab in patients with chronic spontaneous urticaria inadequately controlled with H1-antihistamines, Professor Gordon Sussman provided the results of an exploratory analysis of the Phase 2b extension study.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

EADV Virtual 2020

Explore this section for the latest updates in chronic spontaneous urticaria treatment and management from the European Academy of Dermatology and Venereology (EADV) International Congress 2020 Virtual, including an expert summary interview with Professor Marcus Maurer.

EADV Virtual 2020 – Overview

At EADV Virtual 2020, the 29th European Academy of Dermatology and Venereology (EADV) congress, new frontiers in dermatology and venereology were explored. In these daily blogs we show you some of the exciting sessions on chronic spontaneous urticaria that were discussed at EADV 2020. Find out more below

From 29th – 31st of October 2020, thousands of healthcare professionals and scientists from around the world came together online to explore the latest updates in dermatology and venereology.

Don’t worry if you couldn’t make it to EADV virtual this year. In the next few blog posts, we explore sessions which featured fascinating new insights related to the diagnosis and treatment of chronic spontaneous urticaria (CSU).

Day 1: Diagnosis and management of CSU

On the first day of EADV virtual, we followed sessions on the diagnosis and management of chronic spontaneous urticaria and the impact of coronavirus disease 2019 (COVID-19).

Professor Torsten Zuberbier, Dr Tabi Anika Leslie, Associate Professor Emek Kocatürk Göncü and Dr Dagmar Simon share their knowledge on the pathogenesis, differential diagnosis and management of chronic spontaneous urticaria.

Day 2: Phenotypes, biomarkers and targeting the wheal

Day two had insightful sessions discussing phenotypes, biomarkers and new treatments in chronic spontaneous urticaria.

A stimulating session chaired by Professor Marcus Maurer, and joined by Professor Ana Giménez-Arnau, discussed biomarkers for phenotypes of chronic spontaneous urticaria, news in inducible urticarias, and new treatments targeting wheals – the classic skin lesions of urticaria.

We also take a look at an ePoster by Dr Dhiraj Dhoot focusing on the effect of bilastine on chronic spontaneous urticaria refractory to levocetrizine.

Day 3: Exploring study outcomes for CSU

On the final day we learned the results of the PREG-CU study with Associate Professor Emek Kocatürk Göncü. This study is designed to elucidate treatment patterns and outcomes in patients with chronic urticaria during pregnancy.

We also found out the results of an analysis of the first 12 weeks of a Phase 2b study comparing ligelizumab and omalizumab in their ability to achieve symptom control in patients with chronic spontaneous urticaria, presented by Professor Marcus Maurer.

Even more at EADV Virtual

In addition to the thought-provoking sessions we highlight, EADV virtual was packed with a huge range of other interesting sessions.

From advanced techniques like spectral-domain optical coherence tomography to determining quality of life in patients and assessing newly modified guidelines for the treatment of chronic spontaneous urticaria, EADV virtual was a unique experience.

So, if you couldn’t make it, read our next post where we share our rundown of the events of the first day, giving you a brief overview of some of the essential sessions on the diagnosis and management of chronic spontaneous urticaria at EADV virtual 2020.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Expert opinion

Meet Professor Marcus Maurer

Have you read the recent EAACI/GA2LEN/EDF/WAO 2017 guidelines14? What do you think of the most recent treatment algorithm for patients with CSU? Here, Professor Marcus Maurer, an expert in CSU and last author of the latest guideline revision, sheds light on all that is new in CSU in these bite-sized videos. 

Whats new in CSU? An expert interview with Professor Marcus Maurer

Professor Maurer introduces himself and outlines the topics covered in this session.

Updated EAACI CSU 2017 guidelines - what's new?

Professor Maurer highlights the key changes in the EAACI/GA2LEN/EDF/WAO 2017 guidelines, including treatment choices.
4
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Patient Case Studies

Studying real-life patient cases is a beneficial way to examine the practical application of acquired knowledge. Explore:

  • Dr Sophia Neisinger discuss the CRUSE App to measure patient-reported outcomes (PROs)
  • Professor Emek Kocatürk unpack managing chronic urticaria during pregnancy
  • Professor Jonathan Bernstein examine chronic urticaria in older adults
  • Dr Pavel Kolkhir describe a case of chronic spontaneous urticaria and chronic inducible urticaria

Patient-reported outcome measures

The CRUSE App for remote management of urticaria

Dr Sophia Neisinger

Chronic Spontaneous Urticaria with Isolated Angioedema

Dr Karsten Weller

Join Dr Karsten Weller of the Department of Dermatology and Allergy Charité, Universitätsmedizin Berlin as he describes a clinical case study of isolated angioedema, the route to diagnosis, and guidelines to overcome unsatisfactory treatment to phase 1 treatment.

12

Challenging Cases of CSU

A case of chronic urticaria during pregnancy

Professor Emek Kocatürk

A case of chronic urticaria in the elderly

Professor Jonathan Bernstein

A case of chronic spontaneous urticaria plus chronic inducible urticaria

Dr Pavel Kolkhir

6

Patient Perspectives in CSU

Two CSU sufferers, Daniel and Meritxell, reflect on their personal experiences living with this debilitating condition.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica GW, Church MK, et al. Definition, aims, and implementation of GA2LEN Urticaria Centers of Reference and Excellence. Allergy Eur J Allergy Clin Immunol. 2016;71(8):1210–1218.
  2. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: The 2013 revision and update. Allergy Eur J Allergy Clin Immunol. 2014;69(7):868–887.
  3. Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K, et al. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. International Archives of Allergy and Immunology. 2020;181(5):321–333.
  4. Deza G, Giménez-Arnau AM. Itch in Urticaria Management. Curr Probl Dermatology. 2016;50:77–85.
  5. UCARE. Ucare: a Ga2Len Network. https://www.ga2len-ucare.com/fileadmin/Documents/UCARE_04092020.pdf.
  6. Gasser P, Tarchevskaya SS, Guntern P, Brigger D, Ruppli R, Zbären N, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165.
  7. Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. New treatments for chronic urticaria. Ann Allergy, Asthma Immunol. 2020;124(1):2–12.
  8. Maurer M, Raap U, Staubach P, Richter-Huhn G, Bauer A, Oppel EM, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy. 2019;49(5):655–662.
  9. Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, et al. Ligelizumab for Chronic Spontaneous Urticaria. N Engl J Med. 2019;381(14):1321–1332.
  10. Engin B, Uguz F, Yilmaz E, Özdemir M, Mevlitoglu I. The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria. J Eur Acad Dermatology Venereol. 2008;22(1):36–40.
  11. Kang MJ, Kim HS, Kim HO, Park YM. The impact of chronic idiopathic urticaria on quality of life in Korean patients. Ann Dermatol. 2009;21(3):226–229.
  12. O’Connell PJ, Zhang W, Menon MC, Yi Z, Schröppel B, Gallon L, et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet. 2016;388(10048):983–993.
  13. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy Eur J Allergy Clin Immunol. 2011;66(3):317–330.
  14. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy Eur J Allergy Clin Immunol. 2018;73(7):1393–1414.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: